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Abstract
Tight regulation of vascular permeability is necessary for normal development and deregulated vascular barrier
function contributes to the pathogenesis of various diseases, including acute respiratory distress syndrome, cancer
and inflammation. The angiopoietin (Ang)-Tie2 pathway is known to control vascular permeability. However, the
mechanism by which the expression of Tie2 is regulated to control vascular permeability has not been fully
elucidated. Here we show that transcription factor Twist1 modulates pulmonary vascular leakage by altering the
expression of Tie2 in a context-dependent way. Twist1 knockdown in cultured human lung microvascular endothelial
cells decreases Tie2 expression and phosphorylation and increases RhoA activity, which disrupts cell-cell junctional
integrity and increases vascular permeability in vitro. In physiological conditions, where Ang1 is dominant, pulmonary
vascular permeability is elevated in the Tie2-specific Twist1 knockout mice. However, depletion of Twist1 and
resultant suppression of Tie2 expression prevent increase in vascular permeability in an endotoxin-induced lung
injury model, where the balance of Angs shifts toward Ang2. These results suggest that Twist1-Tie2-Angs signaling is
important for controlling vascular permeability and modulation of this mechanism may lead to the development of
new therapeutic approaches for pulmonary edema and other diseases caused by abnormal vascular permeability.
Citation: Mammoto T, Jiang E, Jiang A, Lu Y, Juan AM, et al. (2013) Twist1 Controls Lung Vascular Permeability and Endotoxin-Induced Pulmonary
Edema by Altering Tie2 Expression . PLoS ONE 8(9): e73407. doi:10.1371/journal.pone.0073407
Editor: You-Yang Zhao, University of Illinois College of Medicine, United States of America
Received March 2, 2013; Accepted July 20, 2013; Published September 2, 2013
Copyright: © 2013 Mammoto et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits
unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Funding: This study was supported by funds from American Heart Association (to A.M.), William Randolph Hearst Award (to A.M.), American Brain Tumor
Association (to A.M.), Children¹s Hospital Boston Faculty Career Development Fellowship (to T.M.), NIDCR/NIH Grant DE021773 (to Y.L.), DoD grant
W81XWH-05-1-0115, Charles H. Hood Foundation (to J.C.), Blind Childrens Center and Boston Children's Hospital Ophthalmology Foundation (to J.C.),
and CHB IDDRC (P30 HD18655). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the
manuscript.
Competing interests: Co-author Jing Chen is a PLOS ONE Editorial Board member. This does not alter the authors' adherence to all the PLOS ONE
policies on sharing data and materials.
* E-mail: Akiko.Mammoto@childrens.harvard.edu
Introduction
Tightly regulated vascular permeability is indispensable for
organ development and function [1], while compromised
vascular barrier function contributes to many pathological
conditions, including acute respiratory distress syndrome
(ARDS), atherosclerosis, cancer, and organ failure [1–7]. A
number of soluble inflammatory regulators such as vascular
endothelial growth factor (VEGF) [4,8], tumor necrosis factor
(TNF)-α [9], transforming growth factor (TGF)-β [10], and IL2
[11] as well as their receptors are known to regulate endothelial
barrier function. In addition, recently, we and other groups have
reported that the angiopoietin (Ang) -Tie2 pathway mediates
endotoxin-induced lung injury [3,12,13] and bronchopulmonary
dysplasia (BPD) [14], a neonatal lung injury accompanied by
an increase in lung vascular permeability [15,16]. However, the
precise mechanism by which Tie2 expression is controlled and
regulates vascular permeability remains to be elucidated.
Twist1, a transcription factor identified in mouse by its high
similarity to Drosophila Twist [17], controls mammalian
embryonic development, including limb budding and cranial
neural tube closure [18–21]. Mouse embryos homozygous for
the Twist1-targeted mutation die at E11.5 because of failure of
cranial neural tube closure [21,22]. Twist1 also contributes to
normal and tumor angiogenesis [23–26] as well as the
epithelial-mesenchymal transition in lung fibrosis [27] and lung
cancer [28], where vascular permeability is increased.
Importantly, Twist1 has a b-HLH sequence that binds to a
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consensus sequence called an E-box (CANNTG) [18,29],
which is present in the promoter region of Tie2 [30]. Given that
the Ang-Tie2 pathway mediates endotoxin-induced lung injury
[3,12] and that Tie2 has an E-box region in its promoter region
[30], Twist1 may control lung vascular barrier function by
modulating the expression of Tie2.
ARDS is a life-threatening respiratory complication that often
accompanies sepsis. In ARDS, increased lung vascular
permeability causes pulmonary edema [31,32], which impairs
gas exchange across the alveolar membrane and severely
compromises respiratory function. ARDS occurs in almost half
of human patients with severe sepsis [31], and the mortality
rate of sepsis-induced ARDS is higher than 60% [33]. Despite
a large amount of effort to develop specific clinical therapies for
ARDS, currently there is no efficient therapy for this
devastating disease or any other conditions accompanied by
abnormal vascular permeability.
In this study, we show that Twist1 knockdown disrupts cell-
cell junctional integrity and increases vascular permeability by
suppressing Tie2 expression in vitro and in vivo. We also show
that downregulation of Twist1-Tie2 signaling prevents increase
of lung vascular permeability and restores lung function in a
mouse endotoxin-induced lung injury model. The Twist1-Tie2
pathway might therefore represent a new target for therapeutic
strategies for sepsis-induced ARDS.
Results
Twist1 knockdown decreases Tie2 expression in vitro
Twist1 is a b-HLH transcription factor which binds to the E-
box promoter region [18,29]. Since the Tie2 promoter has E-
box consensus sequences [30], we first examined whether
Twist1 controls Tie2 expression in lung human microvascular
endothelial (L-HMVE) cells in vitro. Knockdown of Twist1 using
siRNA (#1) transfection, which decreased Twist1 expression
levels by half, downregulated mRNA levels of Tie2 in L-HMVE
cells by half (Figure 1A). Knockdown of Twist1 also
downregulated protein levels of Twist1 and Tie2 in L-HMVE
cells when analyzed using immunoblotting (Figure 1B). Similar
knockdown effects on Tie2 were obtained using a second
Twist1 siRNA (#2), suggesting that the knockdown effect of
Twist1 is not an off-target effect of siRNA (Figure 1A, B). Since
Twist1 is a transcription factor, we next examined whether
Twist1 binds the Tie2 promoter region in L-HMVE cells using
chromatin immunoprecipitation (ChIP) assay [34] (Figure 1C).
ChIP analysis showed that Twist1 binds the Tie2 promoter
region (-666--455), which includes the E-box, and Twist1
knockdown using siRNA (#1) transfection resulted in
decreased binding, indicating that Twist1 binds the Tie2
promoter. Control IgG did not immunoprecipitate these DNAs in
L-HMVE cells (Figure 1C).
Twist1 knockdown increases vascular permeability in
vitro
Since Tie2 is known to control vascular permeability [3,12]
and our in vitro results indicate that Twist1 controls Tie2
expression (Figure 1), we next explored the possibility that
Twist1 might be involved in control of vascular barrier function.
VE-cadherin-containing cell-cell junctions resist the traction
forces generated in the contractile actin cytoskeleton in cells,
and hence control vascular permeability [3].
Immunocytochemical analysis revealed that normally well-
defined, linear cell-cell junctions were disrupted when Twist1
mRNA and protein levels were knocked down in cultured L-
HMVE cells using two distinct siRNAs (#1 and #2) (Figures 1
and 2A). Quantitative results revealed that the discontinuous
area was increased by 3 times in Twist1 knockdown cells
Figure 1.  Twist1 controls Tie2 expression in
microvascular endothelial cells.  A) Graph showing Twist1
and Tie2 mRNA levels in L-HMVE cells treated with Twist1
siRNA #1 or #2 (* p<0.01). As a control, cells were treated with
siRNA duplex with an irrelevant sequence. Error bars represent
s.e.m. of at least three independent experiments. B)
Immunoblots showing Twist1, Tie2, and GAPDH protein levels
in L-HMVE cells treated with Twist1 siRNA #1 or #2. C) ChIP
analysis showing Tie2 promoter co-immunoprecipitating (IP)
with control IgG or Twist1 antibody in L-HMVE cells transfected
with Twist1 siRNA #1. Ct, control.
doi: 10.1371/journal.pone.0073407.g001
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compared to L-HMVE cells treated with control siRNA with
irrelevant sequence (Figure 2B). Twist1 knockdown also
increased vascular permeability by 1.3-fold as measured by
quantitating the flux of fluorescently-labeled albumin across the
cell monolayer cultured in a Transwell chamber in vitro (Figure
2C) [3]. These knockdown effects were obtained by two distinct
siRNAs against Twist1, suggesting that these knockdown
effects of Twist1 siRNA on cell-cell junction integrity are not off-
target effects of siRNA (Figure 2A–C) and we used Twist1
siRNA #1 for the rest of the experiments. It has been reported
that phosphorylation of the Tie2 receptor and subsequent
change in Rho small GTPase activity control vascular
permeability in both cultured endothelial cells in vitro and in
vivo in lungs [3,12,35]. Thus, we next examined whether Twist1
controls Tie2 phosphorylation and RhoA activity in L-HMVE
cells. Twist1 knockdown significantly decreased Tie2
expression as well as Tie2 phosphorylation in L-HMVE cells
(Figure 2D). When we examined RhoA activity using a rhotekin
pull down assay, RhoA activity was three times higher in
Twist1-knocked down L-HMVE cells compared to cells treated
with control siRNA with irrelevant sequence (Figure 2E).
Importantly, when we over-expressed Tie2 in HUVE cells using
DNA transfection, the Twist1 knock down-induced vascular
leakage was partially inhibited (Figure 2F). These results
indicate that Twist1 regulates vascular permeability by
changing the expression levels and associated phosphorylation
status of Tie2 and changing RhoA activity in microvascular
endothelial cells.
Twist1 knockdown increases vascular permeability in
the mouse lung in vivo
To further evaluate the role of Twist1 in vascular permeability
in vivo, we created Tie2-specific conditional Twist1 knockout
mice (Tie2-Twist1KO) by crossing Tie2-Cre expressing mice
with Twist1flox|flox mice exhibiting floxed disruption in the Twist1
gene. Histology (H & E staining) of lung sections revealed that
the interstitial wall is thicker throughout the lungs of Tie2-
Twist1KO mice (Figure 3A, 6 weeks old) compared to the lungs
of age matched control Twist1flox|flox mice. Twist1 and Tie2
mRNA expression decreased by 50% and 20% respectively in
the whole lungs of Tie2-Twist1KO mice (Figure 3B), which is
consistent with the in vitro data showing that knockdown of
Twist1 decreases Tie2 expression (Figure 1). The expression
of the Tie2 ligands, Ang1 and 2, was not altered in the lungs of
Tie2-Twist1KO mice compared to that in control Twist1flox|flox
mice (Figure 3B). We also examined the degree of Twist1 and
Tie2 inhibition in endothelial cells of Tie2-Twist1KO mouse lungs
using laser capture microdissection (LCM) on unfixed frozen
sections of lung tissue. We collected concanavalin A labeled
endothelial cells and measured mRNA levels of Twist1 and
Tie2 in endothelial cells using qRT-PCR. Twist1 and Tie2
expression were lower by 90% and 75%, respectively in lung
endothelial cells from Tie2-Twist1KO mice compared to that in
control Twist1flox|flox mice (Figure 3C). We also enzymatically
digested lungs of these mice and isolated endothelial cells by
incubating these cells with CD31-coated beads and analyzed
the protein levels of Twist1 and Tie2 in the cells using
immunoblotting. Consistent with the results obtained by LCM,
Twist1 and Tie2 expression were lower by 98% and 65%,
respectively in lung endothelial cells collected from Tie2-
Twist1KO mice compared to cells from control Twist1flox|flox mice
(Figure 3D). We further confirmed the results using
immunohistochemical analysis, showing that Twist1 and Tie2
expression were lower in CD31-positive endothelial cells of
Tie2-Twist1KO mouse compared to those of control Twist1flox|flox
mouse (Figure 3E). The junctional integrity and endothelial
microstructure of the lungs were also analyzed in control
Twist1flox|flox and Tie2-Twist1KO mouse lungs using transmission
electron microscopy (TEM). Junctions between pulmonary
endothelial cells were tight and characterized by closely
apposed membranes in randomly sampled regions of lungs
from control Twist1flox|flox mice. In contrast, in lungs from Tie2-
Twist1KO mice, endothelial cells were swollen with cubical
shape and cell-cell junctions appeared to be disrupted with
increased space appearing between adjacent cell membranes
(Figure 3F). These findings support the hypothesis that Twist1-
Tie2 signaling plays a key role in endothelial cell structure and
junctional integrity in vivo.
To further determine whether changes in Twist1 expression
regulate pulmonary vascular permeability in vivo, we measured
vascular permeability in Tie2-Twist1KO mouse lungs by
measuring leakage of Evans blue dye (Figure 4A) or
fluorescently labeled low molecular weight (LMW) dextran
(Figure 4B). The leakage of Evans blue dye into lung
extravascular space was 1.8 times higher in Tie2-Twist1KO
mouse lungs compared to that in Twist1flox|flox control mice
(Figure 4A). The leakage of fluorescently labeled LMW dextran
into lung alveolar spaces also increased by 2.5-fold in Tie2-
Twist1KO mouse lungs compared to that in control Twist1flox|flox
mice (Figure 4B). In addition, Twist1 knockdown in Tie2-
Twist1KO mouse lungs increased the number of immune cells in
bronchoalveolar lavage (BAL) fluid by approximately 3-fold,
further indicating that vascular permeability is increased in
Tie2-Twist1KO mouse lungs (Figure 4C). Exercise capacity as
measured by the total distance mice were able to run using a
rodent treadmill exercise protocol, was decreased by 25% in
Tie2-Twist1KO mice compared to control Twist1flox|flox mice
(Figure 4D), indicating that Twist1 plays a key role in
physiological lung function. Consistent with the data from in
vitro study, Tie2 overexpression using retro-orbital injection of
cationic DNA [7,36,37], which increases Tie2 protein levels in
the lungs (Figure S1A), partially restored lung vascular leakage
in Tie2-Twist1KO mice (Figure 4E), confirming that Twist1-Tie2
signaling controls lung vascular barrier function in vivo.
Twist1-Tie2 signaling mediates endotoxin-induced lung
injury
Circulating serum Ang2 is elevated in humans with various
pathological conditions such as ARDS, cancer and
inflammation, in which vascular permeability is elevated
[12,13,38–41]. Although Twist1 knockdown using siRNA
transfection disrupted cell-cell junctional integrity in L-HMVE
cells, when cells were treated with Ang2, Twist1 knockdown
failed to disrupt cell-cell junctional integrity (Figure 5A).
Quantitative results revealed that the discontinuous area was
increased by 3-fold in Twist1 knockdown L-HMVE cells, which
Twist1 in Pulmonary Vascular Permeability
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Figure 2.  Twist1 controls the integrity of endothelial cell-cell junction in microvascular endothelial cells in vitro.  A)
Immunofluorescence micrographs showing cell-cell junction structure by VE-cadherin staining in L-HMVE cells treated with Twist1
siRNA #1 or #2 (bar, 50 µm). DAPI staining shows the nuclei of cells. Arrows show the region where cell-cell junctions are disrupted.
As a control, cells were treated with siRNA duplex with an irrelevant sequence. B) Graph showing the quantitation of the total
discontinuous area of at least 10 fields (*, p<0.01). C) Graph showing endothelial permeability in L-HMVE cells treated with control
siRNA, Twist1 siRNA #1 or #2 (*, p<0.05). Permeability (Pa) values were evaluated after 6 h and are expressed as percentage of
control cells. D) Immunoblots showing tyrosine phosphorylated Tie2 detected by phosphotyrosine antibody (4G10) and total Tie2
immunoprecipitated with Tie2 antibody from total cell lysates in Twist1 knockdown (siRNA #1 treated) L-HMVE cells. E) Levels of
active RhoA in Twist1 knockdown (siRNA #1 treated) L-HMVE cells. Quantitative results (ratio of active RhoA to total RhoA) were
normalized to control siRNA treated cells (*, p<0.01). F) Graph showing endothelial permeability in HUVE cells treated with Twist1
siRNA #1, Tie2 DNA, or in combination (*, p<0.05). As a control, cells were treated with siRNA duplex with an irrelevant sequence
and/or control DNA (vector only). Immunoblots showing Twist1, Tie2, and GAPDH protein levels in HUVE cells treated with Twist1
siRNA #1, Tie2 DNA, or in combination. All error bars are s.e.m.
doi: 10.1371/journal.pone.0073407.g002
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Figure 3.  Twist1 regulates endothelial microstructure and cell-cell junctional integrity in the mouse lung in vivo.  A) H&E
staining of the lungs from control Twist1flox|flox or Tie2-Twist1KO mice. Scale bar, 50 µm. B) Graph showing Twist1, Tie2, and Ang1, 2
mRNA levels in the lungs of Twist1flox|flox or Tie2-Twist1KO mice (n=8, * p<0.05). Error bars are s.e.m. C) Graph showing Twist1 and
Tie2 mRNA levels in the lung blood vessels of Twist1flox|flox or Tie2-Twist1KO mice isolated using LCM (* p<0.05). Error bars are
s.e.m. D) Immunoblots showing Twist1, Tie2 and GAPDH protein levels in CD31 positive cells isolated from Twist1flox|flox or Tie2-
Twist1KO mice (left). Graphs showing the quantitative results of protein levels of Twist1 and Tie2 normalized to GAPDH protein
levels (right). E) Immunofluorescence micrographs showing expression and distribution of Twist1, Tie2 and CD31-stained blood
vessels in the lungs of Twist1flox|flox or Tie2-Twist1KO mice (bar, 20 µm). F) TEM images showing endothelial microstructure and cell-
cell junctional integrity in the lungs of Twist1flox|flox or Tie2-Twist1KO mice (bar, 500 nm). E: endothelial cells. Arrowheads show the
region of cell-cell junctions.
doi: 10.1371/journal.pone.0073407.g003
Twist1 in Pulmonary Vascular Permeability
PLOS ONE | www.plosone.org 5 September 2013 | Volume 8 | Issue 9 | e73407
Figure 4.  Twist1 regulates lung vascular permeability in vivo.  A) Graph showing vascular permeability in the lungs of Twist1flox|
flox or Tie2-Twist1KO mice. Vascular permeability is detected by Evans blue dye leakage in the lungs and extracted dye contents are
quantified by measuring at 620 nm (n=9, *, p<0.05). B) Immunofluorescence micrographs showing LMW fluorescently labeled
dextran leakage (green) and blood vessel formation (CD31 staining; magenta) in the lungs of Twist1flox|flox or Tie2-Twist1KO mice (bar,
20 µm). Graph showing the leaked dextran density normalized to vessel density in the lungs of Twist1flox|flox or Tie2-Twist1KO mice
(n=7, *, p<0.05). C) Micrographs showing the immune cells in BAL fluid from the lungs of Twist1flox|flox or Tie2-Twist1KO mice detected
by Wright-Giemsa staining (Upper, bar, 50 µm). Graph showing the immune cell count in BAL fluid from the lungs of Twist1flox|flox or
Tie2-Twist1KO mice (Lower, n=8, *, p<0.05). D) Exercise capacity of Twist1flox|flox or Tie2-Twist1KO mice assessed by total running
distance according to a predetermined protocol (n=15, *, p<0.05). E) Graph showing vascular permeability detected by Evans blue
dye leakage in the lungs of Twist1flox|flox or Tie2-Twist1KO mice treated with Tie2 DNA (left; n=9, *, p<0.05). Immunofluorescence
micrographs showing LMW fluorescently labeled dextran leakage (green) and blood vessel formation (CD31 staining; magenta) in
the lungs of Twist1flox|flox or Tie2-Twist1KO mice treated with Tie2 DNA (right; bar, 20 µm). Graph showing the leaked dextran density
normalized to vessel density in the lungs of Twist1flox|flox or Tie2-Twist1KO mice treated with Tie2 DNA (n=7). As a control, mice were
treated with control DNA (vector only). All error bars are s.e.m.
doi: 10.1371/journal.pone.0073407.g004
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was restored to the levels of untreated control cells when
treated with Ang2 (Figure 5B). Consistently, Twist1 knockdown
failed to increase vascular permeability, measured using a
transwell vascular permeability assay, under Ang2 treatment in
L-HMVE cells (Figure 5C). When we measured the mRNA and
protein levels of Twist1 and Tie2 in L-HMVE cells, they were
60-70% lower in Twist1-knocked down Ang2-treated L-HMVE
cells, which were identical to untreated cells (Figure 5D),
suggesting that Ang2 does not affect the Twist1 knockdown-
induced decrease in Tie2 expression. We also examined
whether Twist1 controls RhoA activity in Ang2-treated L-HMVE
cells. When we examined RhoA activity using a rhotekin pull
down assay, RhoA activity was lower by 30% in Twist1-
knocked down Ang2-treated L-HMVE cells compared to the
cells treated with Ang2 and control siRNA with irrelevant
sequence (Figure 5E).
To determine whether Twist1-Tie2 signaling mediates lung
vascular permeability in sepsis-induced lung injury in vivo, we
exposed whole lung of living adult mice to the endotoxin,
lipopolysaccharide (LPS), which induces the development of
pulmonary edema and ARDS in humans with sepsis [3,42].
Systemic LPS treatment is a widely accepted physiological
animal model for sepsis-induced ARDS [3,7,31,43]. Consistent
with previous reports [3,7], LPS treatment for 24 hours in
control Twist1flox|flox mice increased lung vascular permeability
by 2.5-fold compared to untreated control mice when measured
using Evans blue dye leakage (Figure 6A). LPS-induced
increase in lung vascular permeability was significantly
suppressed in Tie2-Twist1KO mice, in which Tie2 expression in
lungs was decreased (Figure 3B–E), compared to control
Twist1flox|flox mice (Figure 6A). We also confirmed the effects of
LPS treatment in Tie2-Twist1KO mice using fluorescent-labeled
LMW dextran leakage, showing that increased dextran leakage
into alveolar spaces was 15% lower in Tie2-Twist1KO mice
compared to Twist1flox|flox mice (Figure 6B). Consistently, the
number of immune cells in the BAL fluid increased by 4.5-fold
in the LPS-treated control Twist1flox|flox mice, while this effect
was attenuated in the Tie2-Twist1KO mice (Figure 6C, D).
These results suggest that down-regulated Twist1-Tie2
signaling suppresses endotoxin-induced vascular leakage in
mouse lungs. Consistent with in vitro results (Figure 5D), the
mRNA and protein levels of Twist1 and Tie2 in the lungs were
30-70% lower in Tie2-Twist1KO mice regardless of LPS
treatment (Figure 6E, Figure S2). Importantly, LPS treatment
significantly increased the protein levels of Ang2 in the lungs,
while it did not change Ang1 levels (Figure 6E), suggesting that
downregulation of Twist1-Tie2 signaling prevents the LPS-
induced increase in lung vascular permeability by suppressing
the effects of its ligand, Ang2, on endothelial cell-cell junctional
integrity. Although basal exercise capacity measured using a
rodent treadmill exercise protocol was significantly lower in
LPS-treated Twist1flox|flox mice compared to untreated mice,
when evaluated 1 week after the LPS treatment, the running
ability was partially reversed in LPS-treatedTwist1flox|flox mice
(Figure 6F). These findings suggest that down-regulation of
Twist1-Tie2 signaling attenuates the endotoxin-induced
increase in vascular permeability and restores lung function.
Discussion
Tightly regulated vascular permeability is critical to maintain
lung function, while deregulated vascular permeability
contributes to the pathogenesis of acute lung injury and ARDS
[3,31,32]. Here we show that Twist1 controls lung vascular
permeability by altering Tie2 expression. In physiological
conditions where the ratio of Ang1 and Ang2 is in favor of
Ang1, knockdown of Twist1 decreases Tie2 expression and
hence increases lung vascular permeability in cultured L-HMVE
cells in vitro and in adult mouse lung in vivo. However, in
pathological conditions in which Ang2 is upregulated
[12,13,38], downregulation of Twist1-Tie2 signaling prevents
the increase of vascular leakage in the lungs by attenuating the
vessel-destabilizing effects of Ang2 (Figure 7). These findings
suggest that Twist1- Tie2 signaling in combination with the
signatures of Angs regulates lung vascular permeability in a
context-dependent way. Since the detrimental effects of
endotoxin on pulmonary vascular permeability can be
prevented by suppressing Twist1 expression, targeting the
Twist1-Tie2 pathway could potentially lead to the development
of new approaches for sepsis-induced ARDS and other
diseases with abnormal vascular permeability in the future.
Our results revealed that Tie2 overexpression partly, but not
completely, restored the Twist1 knockdown-induced lung
vascular leakage in vitro and in vivo. Given that Twist1 has a b-
HLH sequence, which binds to an E-box sequence [18,29], and
that E-box also exists in the promoter region of VEGFR2 [44]
and VE-cadherin [45], which also control cell-cell junctional
integrity and vascular permeability, Twist1 may control cell-cell
junctional integrity and vascular permeability by modulating the
expression of these molecules as well. In fact, Twist1
knockdown in L-HMVE cells decreased the expression of
VEGFR2 at both mRNA and protein levels (Figure S1B). Thus,
Twist1 may alter lung vascular permeability by changing the
expression of VEGFR2 as well. Our finding showing that Twist1
as a regulator of Tie2 expression could be quite important as a
general mechanism of endothelial Tie2 expression. Tie2
mediates physiological angiogenesis [46–48] and deregulation
of this mechanism contributes to various pathological
conditions such as bronchopulmonary dysplasia (BPD) [14]
and tumor angiogenesis [49]. Since Twist1 positively regulates
tumor angiogenesis [50,51], Twist1-Tie2 signaling may be
involved in the mechanisms of tumor-angiogenesis as well, in
which vascular permeability is increased. Further investigation
of the roles of the Twist1-Tie2 pathway on physiological and
pathological angiogenesis as well as vascular barrier function
will likely expand our scientific knowledge and lead to the
development of new therapeutic strategies for angiogenesis-
related diseases.
It has been known that Ang1 and Ang2 bind to their common
receptor Tie2, antagonize each other and control blood vessel
maturation and stabilization [52]; Ang1 stabilizes blood vessel
formation [3,52–54], whereas Ang2 destabilizes the blood
vessel structure and increases vascular permeability in lung
injury [12,13,55–57], tumors [39–41] and lung fibrosis [58,59].
Our findings suggest that downregulation of Twist1 expression
inhibits the Ang1-induced vascular stabilization in physiological
Twist1 in Pulmonary Vascular Permeability
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Figure 5.  Twist1 knockdown fails to disrupt endothelial cell-cell junction integrity in L-HMVE cells under Ang2 treatment in
vitro.  A) Immunofluorescence micrographs showing cell-cell junction structure by VE-cadherin staining in L-HMVE cells treated
with Twist1 siRNA (#1), Ang2, or both in combination (bar, 50 µm). DAPI staining shows the nucleus of each cell. Arrows show the
region where cell-cell junctions are disrupted. As a control, cells were treated with siRNA duplex with an irrelevant sequence. B)
Graph showing the quantitation of the total discontinuous area in L-HMVE cells treated with Twist1 siRNA (#1), Ang2, or both in
combination in at least 10 fields (*, p<0.05). C) Graph showing endothelial permeability in L-HMVE cells treated with Twist1 siRNA
(#1), Ang2, or both in combination (*, p<0.05). Permeability (Pa) values are expressed as percentage of control cells. D) Graphs
showing Twist1 and Tie2 mRNA levels in L-HMVE cells treated with Twist1 siRNA (#1), Ang2, or both in combination (top, * p<0.01).
Immunoblots showing Twist1, Tie2, and GAPDH protein levels in L-HMVE cells treated with Twist1 siRNA (#1), Ang2, or both in
combination (bottom). E) Immunoblots showing levels of active RhoA in L-HMVE cells treated with Twist1 siRNA (#1), Ang2, or both
in combination (top). Quantitative results (ratio of active RhoA to total RhoA) were normalized to control siRNA treated Ang2-
untreated cells (*, p<0.05). All error bars are s.e.m.
doi: 10.1371/journal.pone.0073407.g005
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Figure 6.  Twist1 mediates lung vascular permeability in endotoxin-induced lung injury in vivo.  A) Vascular permeability
detected by Evans blue dye leakage in the lungs of Twist1flox|flox or Tie2-Twist1KO mice treated with LPS for 1 day (n=10, *, p<0.05).
B) Immunofluorescence micrographs showing LMW fluorescently labeled dextran leakage (green) and blood vessel formation
(CD31 staining; magenta) in LPS-treated lungs of Twist1flox|flox or Tie2-Twist1KO mice (bar, 20 µm). Graph showing the leaked dextran
density normalized to vessel density in the lungs of LPS-treated Twist1flox|flox or Tie2-Twist1KO mice (n=7, *, p<0.05). C) Micrographs
showing the immune cells in BAL fluid from the lung of Twist1flox|flox or Tie2-Twist1KO mice treated with LPS for 1 day, detected by
Wright-Giemsa staining (bar, 50 µm). D) Graph showing the immune cell count in BAL fluid from the lungs of Twist1flox|flox or Tie2-
Twist1KO mice treated with LPS for 1 day (n=8, *, p<0.05). E) Immunoblots showing Twist1, Tie2, and β-actin protein levels in the
lungs of Twist1flox|flox (Ct) or Tie2-Twist1KO mice (T) treated with LPS for 1 day (left). Graphs showing Ang1 and Ang2 protein levels in
the lungs of Twist1flox|flox (Ct) or Tie2-Twist1KO mice (T) treated with LPS for 1 day (right, n=8, * p<0.05). F) Exercise capacity of
Twist1flox|flox or Tie2-Twist1KO mice treated with LPS for 1 day assessed by total running distance according to a predetermined
protocol (n=15, *, p<0.05). All error bars are s.e.m.
doi: 10.1371/journal.pone.0073407.g006
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conditions, whereas it prevents the Ang2-induced vascular
destabilization in pathological conditions (i.e., endotoxin-
induced lung injury) by decreasing the expression of its
receptor Tie2. This is consistent with our previous report
showing that Tie2 expression controlled by LRP5 and the
balance of Ang1 and Ang2 coordinately regulate lung vascular
development and contribute to the pathogenesis of BPD, in
which lung vascular permeability is elevated [14]. It has been
reported that Twist1 levels are higher in tumors and fibrotic
tissues [24–28,50,60,61], in which Ang2 levels are high and
vascular permeability is elevated. Therefore, in addition to
manipulating the levels of Angs, modulating Tie2 expression
through Twist1 could be a good therapeutic strategy for these
diseases as well.
VEGF is a well-known vascular permeability factor [4,62].
Importantly, when the mouse paw was treated with Ang2 and
VEGF at the same time, the effects were additive, which
suggests that these two factors act independently [63,64].
However, it has also been reported that Ang1 has a protective
function against increased brain barrier permeability caused by
overexpression of VEGF [65]. In addition, Ang2 expression
levels are regulated by VEGF [66] and VEGF-VEGFR2
signaling is known to interact with the Tie2/Angs system to
modulate vascular functions [49,67,68]. Thus, Angs and VEGF
control vascular permeability both independently and
Figure 7.  Twist1 regulates lung vascular barrier function through the Ang-Tie2 pathway.  Vascular permeability in the lung
can be controlled by Twist1-Tie2 signaling depending on the Ang1/Ang2 ratio. In physiological conditions where the ratio of Ang1
and Ang2 is in favor of Ang1, knockdown of Twist1, which decreases the expression of Tie2, increases vascular permeability in the
lung. However, during a pathological condition such as endotoxin-induced lung injury, in which Ang2 is upregulated [12,13,38],
knockdown of Twist1 fails to increase vascular permeability, rather reverses the increase of vascular leakage in the lungs.
doi: 10.1371/journal.pone.0073407.g007
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cooperatively, and play important roles in angiogenesis, vessel
maturation and inflammation [64].
In addition to soluble angiogenic factors, cell-generated
mechanical forces and adhesive properties to the ECM are
also known to influence angiogenesis and organ
morphogenesis [69,70]. Changes in ECM mechanics (stiffness)
control VEGF-induced angiogenesis [34] and lung vascular
permeability [7]. In fact, endotoxin-treated lungs [7], tumor
tissues [71,72] and fibrotic lungs [73,74], in which microvessels
are hyperpermeable, are accompanied by increased ECM
stiffness. Since Twist expression is induced by mechanical
forces (i.e., physical compression) in the Drosophila embryo
[75,76], in addition to chemical regulators, physical changes in
ECM mechanics might regulate lung vascular permeability via
the Twist1-Tie2 pathway.
In summary, we have demonstrated that Twist1 regulates
Tie2 expression and modulates lung vascular permeability in
an Angs-dependent way. Since inhibition of this pathway
prevents LPS-induced vascular leakage in the lung, the Twist1/
Tie2 system could represent a novel therapeutic target for
ARDS as well as other diseases caused by abnormal vascular
permeability.
Materials and Methods
Materials
Anti -CD31 and –VE-cadherin monoclonal antibodies were
from Transduction Laboratories (Lexington, KY). Anti-GAPDH
monoclonal antibody was from Chemicon (Temecula, CA).
Anti-β actin monoclonal antibody was from Sigma. Anti–Twist1
monoclonal and -RhoA polyclonal antibodies were from
Abcam. Anti–Twist1 polyclonal antibody was from Santa Cruz
Biotechnology (Dallas, TX). Anti-Tie2 monoclonal antibody and
anti-phosphotyrosine (4G10) were from Upstate (Lake Placid,
NY). Anti-VEGFR2 polyclonal antibody was from Cell Signaling
(Danvers, MA). LPS was from Sigma. L-HMVE cells and HUVE
cells (Lonza, Walkersville, MD) were cultured as described
before [3,14].
Plasmid construction and gene knockdown
The full length Tie2 plasmid (pSPORT Tie2) was from Open
Biosystems (Huntsville, AL) and transient transfection was
performed using Superfect reagent (QIAGEN, Valencia, CA)
according to the manufacturer’s directions [34]. As a control,
plasmid with vector only was used. Gene knockdown was
performed using the RNA interference technique [34]. siRNAs
for human Twist1 #1 was 5’-
UUGAGGGUCUGAAUCUUGCUCAGCU -3’ and 5’-
AGCUGAGCAAGAUUCAGACCCUCAA -3’. #2 was 5’-
ACUCCAAGAUGGCAA GCUG-3’ and 5’-
CAGCUUGCCAUCUUGGAGU-3’ [77]. As a control, siRNA
duplex with an irrelevant sequence (QIAGEN) was used.
Biochemical Methods
Rho activity assay was performed and quantified using the
Rho activation assay kit based on rhotekin pull-down assay
according to the manufacturer’s instruction (Cytoskeleton,
Denver, CO) [78]. The ratio of rhotekin-bound RhoA and RhoA
in the total cell lysate was analyzed using NIH ImageJ software
[78]. The levels of Ang1 and Ang2 in the mouse lung
homogenate were measured by ELISA (MyBioSource, San
Diego, CA).
Molecular biological methods
Quantitative reverse transcription (qRT)-PCR was performed
with the Quantitect SYBR, Green RT-PCR kit (Agilent) using
the ABI 7300 real time PCR system (Applied Biosystems,
Foster City, CA). β2 microglobulin or cyclophilin controlled for
overall cDNA content. The primers used for human and mouse
Tie2, mouse Ang1 and Ang2, human VEGFR2, human β2
microglobulin and mouse cyclophilin were previously described
[14,34]. The primers for human Twist1 were 5’-
GTCCGCAGTCTTACGAGGAG-3’, 5’-
GCTTGAGGGTCTGAATCTTGCT-3’, mouse Twist1 were 5’-
GGACAAGCTGAGCAAGATTCA-3’, 5’-
CGGAGAAGGCGTAGCTGAG-3’. For ChIP assay, DNA from
L-HMVE cells transfected with control or Twist1 siRNA #1 was
immunoprecipitated with the Twist1 antibody or control
immunoglobulin (Jackson Immuno Research), according to the
manufacturer instructions (Active Motif, Carlsbad, CA) [34]. The
Twist1-binding region was amplified using primers, 5’-
TTGCTTTTCAGGTTGTATTTTC-3’ and 5’-
agaataacaagccctccacc-3’.
Cell analysis methods
L-HMVE cell monolayer junction formation was analyzed
using immunohistochemistry with VE-cadherin antibody
staining [3,7,34]. L-HMVE cells were cultured for 12 h and
immunostaining was performed and analyzed using confocal
Leica SP2 microscope [34]. Discontinuous area was calculated
using ImageJ software in ten random fields in three
independent experiments [7]. L-HMVE cell monolayer
permeability was determined with the use of FITC-labeled
bovine serum albumin (Sigma) as described previously [3].
FITC-albumin (final concentration 1 mg/ml) was added to the
luminal chamber for 6 h, and samples were taken from both the
luminal and abluminal chamber for fluorometric analysis.
Where indicated, vehicle or Ang2 (30 ng/ml, R&D systems)
was added to the luminal chamber with FITC-labeled bovine
serum albumin. Fluorescence readings were converted with the
use of a standard curve to albumin concentration. These
concentrations were used to determine the permeability
coefficient of albumin (Pa) as described [3].
In Vivo Pulmonary Permeability Assay
The in vivo animal study was carried out in strict accordance
with the recommendations in the Guide for the Care and Use of
Laboratory Animals of the National Institutes of Health. The
protocol was reviewed and approved by the Animal Care and
Use Committee of Boston Children’s Hospital (Protocol
Number: 10-11-1818R). Mice with Tie2-specific knockdown of
Twist1 (Tie2-Twist1KO) were generated by cross-breeding Tie2-
Cre expressing C57BL/6J mice (Jackson Laboratory stock
#004128) with Twist1 floxed mice (Twist1flox|flox) [79]. Mice (6–8
weeks old) were treated with LPS (2.5 mg/kg, intraperitoneally)
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and lung permeability was assessed 24 hours after injection
[3,7]. For gene overexpression, delivery of DNA into mice was
performed using retro-orbital injection of the mixture with Exgen
(Fermentas) according to the manufacturer’s instructions
[7,36,37]. Gene overexpression in the lung (2 days later) was
confirmed by measuring protein levels using immunoblotting.
The lung permeability was measured using Evans blue dye or
LMW fluorescently labeled dextran (MW 4000, sigma) leakage
[3,7]. Evans blue dye was extracted from the lung by incubation
with formamide (70 °C for 24 h) and the absorbance of
extracted dye was measured at 620 nm. Dextran leakage was
quantified using a macro designed for NIH’s ImageJ software
that counts colored pixels between thresholds selected to
minimize background, yielding a percentage of total image
area, which was then normalized to vessel density, with each
parameter analyzed independently.
For TEM, small pieces (1-2 mm cubes) of lung tissue were
fixed with 2.5% Glutaraldehyde and 2% Paraformaldehyde in
0.1 M sodium cacodylate buffer (pH 7.4) for at least 2 h at room
temperature, washed in 0.1M cacodylate buffer and postfixed
with 1% Osmium tetroxide (OsO4)/1.5%
Potassiumferrocyanide (KFeCN6) for 1 h, washed in water and
incubated in 1% aqueous uranyl acetate for 1 h followed by
washes in water and subsequent dehydration in grades of
alcohol. The samples were then put in propylene oxide for 1 hr
and infiltrated ON in a 1:1 mixture of propylene oxide and
TAAB Epon (Marivac Canada Inc, St.-Laurent, Canada). The
samples were then embedded in TAAB Epon and polymerized
at 60 °C for 48 hrs. Ultrathin sections (about 60 nm) were cut
on a Reichert Ultracut-S microtome, picked up on to copper
grids stained with lead citrate and examined in a TecnaiG²
Spirit BioTWIN.
BAL was performed by instilling 0.9% NaCl in two separate
0.5 ml aliquots. The fluid was recovered by gentle suction and
placed on ice for immediate processing. An aliquot of the BAL
fluid was processed immediately for differential cell counts by
performing cytospin preparations and staining with modified
Wright-Giemsa stain (Diff-Quik; American Scientific Products,
McGaw Park, IL) [7].
Laser-Capture Microdissection of Lung Vessels
Lung vessels were microdissected with laser capture in
unfixed cross sections of lungs from Tie2-Twist1KO and
Twist1flox|flox mice, as described previously [80–82]. Lungs from
Tie2-Twist1KO and Twist1flox|flox mice were collected after
injecting fluorescein-conjugated Concanavalin A into the retro-
orbital vein to stain blood vessels [7,34]. Lungs were
embedded in OCT, cut into 8-µm sections, and collected on
RNase-free polyethylene naphthalate membrane slides (Leica).
Blood vessels were microdissected on a LCM system
(LMD-6000; Leica). RNA was extracted from microdissected
tissues (RNeasy Micro Kit; Qiagen), and real-time PCR was
performed.
Isolation of CD31-positive cells from mouse lungs
The lung was minced into small pieces and digested in a
solution of 1 mg/ml collagenase (Sigma, St. Louis, MO) and 2.4
U/ml dispase solution (Collaborative Biomedical Products,
Bedford, MA) for 40 min at 37 °C. Single-cell suspensions were
incubated with anti-CD31 antibody-conjugated microbeads
(Miltenyl Biotec, Auburn, CA, USA) on ice and the CD31-
positive population was isolated according to the
manufacturer’s instruction.
Exercise Capacity
Mice were run according to a predetermined protocol and we
assessed the ability of untrained mice to run for distance
[83,84]. The animals were initially acclimated to the treadmill
environment for 30 min. For warm-up and for further
familiarization with treadmill running, the mice were required to
run at a relatively easy pace of 10 m/min for 30 min. Then the
speed of the treadmill was increased to 20 m/min, and we
recorded the exercise duration and distance the mice could run
until exhaustion. Exhaustion was defined operationally as the
time at which the mouse was unable, or refused, to maintain its
running speed despite encouragement by mild electrical
stimulation.
Statistical analysis
All phenotypical analysis was performed by masked
observers unaware of the identity of experimental groups. All
statistical data was analyzed using GraphPad Prism V 5.0.
Error bars (SEM) and p values were determined from the
results at least three or more independent experiments. The
ANOVA with post-hoc student T test was used for analysis of
statistical significance.
Supporting Information
Figure S1.  Tie2 overexpression in mouse lungs and
VEGFR2 expression in Twist1 knockdown L-HMVE cells.
A) Immunoblots showing Tie2 and GAPDH protein levels in
mouse lungs treated with Tie2 DNA. As a control, mouse was
treated with control DNA (vector only). B) Immunoblots
showing VEGFR2, Twist1 and GAPDH protein levels in L-
HMVE cells treated with Twist1 siRNA #1 (left). Graph showing
Twist1 and VEGFR2 mRNA levels in L-HMVE cells treated with
Twist1 siRNA #1 (* p<0.01). As a control, cells were treated
with siRNA duplex with an irrelevant sequence. Error bars
represent s.e.m. of at least three independent experiments.
(TIF)
Figure S2.  Expression of Twist1 and Tie2 in LPS-treated
lungs in vivo. Graphs showing Twist1 and Tie2 mRNA levels
in the lungs of Twist1flox|flox (Ct) or Tie2-Twist1KO (T) mice
treated with LPS (n=8, * p<0.05). Error bars are s.e.m.
(TIF)
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